[Mitral regurgitation associated with heart failure].
Otsuji
Yutaka
Y
Second Department of Internal Medicine, University of Occupational and Environmental Health, Japan School of Medicine.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage; D006348:Cardiac Surgical Procedures; D017548:Echocardiography, Transesophageal; D006333:Heart Failure / Q000209:etiology*; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D006979:Hyperthermia, Induced; D008944:Mitral Valve Insufficiency / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D020257:Ventricular Remodeling; D014859:Warfarin / Q000008:administration & dosage
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D014859:Warfarin